| Druas for Alzheimer's disease: best avoided. No therapeutic advantage. | |
| | |
MedLine Citation:
|
PMID: 22822592 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The French Pharmacoeconomic Committee that assesses the medical benefit of new drugs and provides recommendations about reimbursement has downgraded its rating of the medical benefit (SMR, service mddical rendu) provided by cholinesterase inhibitors and memantine in Alzheimer's disease from "major" to "low". |
| | |
Authors:
|
- |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Prescrire international Volume: 21 ISSN: 1167-7422 ISO Abbreviation: Prescrire Int Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-07-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9439295 Medline TA: Prescrire Int Country: France |
Other Details:
|
Languages: eng Pagination: 150 Citation Subset: T |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Next Document: Gabapentin and pregabalin: abuse and addiction.